Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 30;18(6):2119767.
doi: 10.1080/21645515.2022.2119767. Epub 2022 Sep 12.

Review of bimekizumab in the treatment of psoriasis

Sindhuja Koppu  1 , Rohan Singh  1 , Kiranjit Kaur  1 , Steven R Feldman  1   2   3
Affiliations
Review

Review of bimekizumab in the treatment of psoriasis

Sindhuja Koppu et al. Hum Vaccin Immunother. .

Abstract

Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these interleukins and the formation of psoriatic plaques. This review assesses the efficacy, safety, and implications of bimekizumab in the treatment of moderate-to-severe psoriasis. A review of literature was conducted using the PubMed repository in March 2022. Articles in English discussing the use of bimekizumab in the treatment of psoriasis were included. One phase II and four phase III trials were included. During clinical trials, bimekizumab was more efficacious, when compared to placebo, ustekinumab, adalimumab, and secukinumab in the treatment of moderate to severe psoriasis. Bimekizumab is a promising, efficacious, and relatively tolerable emerging systemic treatment for moderate-to-severe plaque psoriasis.

Keywords: Biologics; efficacy; interleukin-17 inhibitor; psoriasis; safety.

PubMed Disclaimer

Conflict of interest statement

Feldman has received research, speaking and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, Eurofins, Informa, UpToDate and the National Psoriasis Foundation. He is founder and part owner of Causa Research and holds stock in Sensal Health. Koppu, Singh, and Kaur have no conflicts to disclose.

References

    1. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020. Apr;182(4):1–8. doi: 10.1111/bjd.18245. PMID: 31225638. - DOI - PMC - PubMed
    1. Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021. Nov 26;22(23):12793. doi: 10.3390/ijms222312793. PMID: 34884596. - DOI - PMC - PubMed
    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020. May 19;323(19):1945–1960. doi: 10.1001/jama.2020.4006. PMID: 32427307. - DOI - PubMed
    1. Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021. June 29;15:247–253. doi: 10.2147/BTT.S290309. PMID: 34239295. - DOI - PMC - PubMed
    1. Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021. May;21(3):170–173. doi: 10.7861/clinmed.2021-0257. PMID: 34001566. - DOI - PMC - PubMed